GlobeNewswire by notified

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Share

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors.
Diane Souza, Member of the Audit and Compensation Committees, and Thomas Südhof, Chairman of the Scientific Committee, will leave the Board of Directors at the end of their second terms. The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office.

The Chairman specified that, in order to prepare as effectively as possible for the end, in 2025, of the term of office as director of Fabienne Lecorvaisier, Chairman of the Audit Committee, the Board of Directors will temporarily comprise 17 members as from the General Shareholder Meeting of April 30, 2024.

Clotilde Delbos is currently director of Axa and Alstom. She held various positions in internal audit, merger and acquisitions and treasury, in California, Brussels and France, notably at Price Waterhouse and the Pechiney group, before becoming Division Chief Financial Officer. In 2012, she joined the Renault Group. In 2016, Clotilde Delbos was appointed Group Chief Financial Officer and Chairman of Board of Directors of RCI Banque. She was then appointed Interim Chief Executive Officer of Renault SA, Deputy Chief Executive Officer of the group and Chief Executive Officer of Mobilize. Clotilde Delbos was awarded the Légion d’Honneur in 2021.

Clotilde Delbos graduated from EM Lyon with a specialization in accounting.

Anne-Françoise Nesmes is currently Chief Financial Officer of Smith + Nephew PLC, a role from which she will step down at the end of the first quarter of 2024. She joined the Board of Compass Group PLC as a non-executive director in 2018 and currently serves as Senior Independent Director, Chair of the Audit Committee and a member of the Corporate Responsibility, Nomination and Remuneration Committees. She held a number of finance positions in international companies before joining GlaxoSmithKline PLC in 1997, where she worked for 16 years, including as Senior Vice President of Finance for global vaccines. She then became Chief Financial Officer of Dechra Pharmaceuticals PLC and Merlin Entertainments PLC (2013-2020).
Anne-Françoise Nesmes holds a Master’s degree from Grenoble Business School and a Master’s degree in Business Administration from Henley Management College. She is also a Chartered Management Accountant.

John Sundy is currently Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic, a machine learning immunology company and is Adjunct Professor of Medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine. He was a tenured faculy member at Duke University before moving to the biotech industry in 2014. Between 2014 and 2021, he held several management positions including Senior Vice President at Gilead Sciences, and Chief Medical Officer at Pandion Therapeutics.
He is also a director of Neutrolis, Inc, and the Childhood Arthritis and Rheumatology Research Alliance, and serves on the Steering Committee of the NIH Immune Tolerance Network.
John Sundy obtained a B.S. in biology from Bucknell University and an M.D./Ph.D from Hahnemann University with a specialization in immunology, and completed clinical training in rheumatology and allergy/immunology at Duke.

Frédéric Oudéa
Chairman of the Board of Directors
“The arrivals of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy will strengthen the Board of Directors’ expertise in finance and science, notably in the field of immunology. I would like to pay tribute to the remarkable contribution of Diane Souza and Thomas Südhof to the work of the Board, and I am delighted that the Board continues to diversify its profiles and competencies, in line with the Group’s strategic developments.”

The composition of the Board’s specialized committees will be reviewed following the Annual General Meeting of Shareholders scheduled for April 30, 2024.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com

Investor Relations
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Tarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cortus Energy AB deltar på Nordbex projektlansering för satsning på koldioxidnegativ elproduktion i Nybro kommun den 18 april17.4.2024 08:00:00 CEST | Pressemelding

Stockholm, den 17 april 2024 PRESSMEDDELANDE Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) deltar på projektlansering om koldioxidnegativ elproduktion, tillsammans med samarbetsparter Nordbex AB (”Nordbex”). Nordbex presenterar sin satsning och ambitionen att göra Nybro kommun koldioxidnegativ innan 2030 genom ett koldioxidnegativt kraftverk med Cortus Energys förgasningsteknologi, WoodRoll®. Under projektlanseringen kommer den svenska projektutvecklaren Nordbex presentera miljardsatsningen på koldioxidnegativ elproduktion som görs i Nybro kommun. Det första koldioxidnegativa kraftverket ska byggas av Nordbex, där Cortus WoodRoll®-förgasningsteknologi har en central roll till följd av den rena syngasen som produceras. Nordbex kraftverk kommer att generera 135 GWh ren energi och samla in 200 000 ton koldioxid från atmosfären varje år. Projektlanseringen inleds med en presentation av Nordbex, vilken går att följa live från och med kl 16:00 den 18 april på följande länk https://www.y

Norsk Hydro: Reminder - Invitation to Hydro's first quarter results 202417.4.2024 08:00:00 CEST | Press release

Hydro's first quarter results 2024 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on Wednesday, April 24, 2024. The quarterly report and presentation will be available on hydro.com at the same time. President and CEO Hilde Merete Aasheim and Executive Vice President, Corporate Development & acting CFO Trond Olaf Christophersen will host a webcast in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no presentation or press conference at our corporate headquarters. To join the webcast and ask questions, register your details in the webcast page. Once registered, you will receive a separate email confirming your registration. The webcast is powered by Livestorm. We advise that you investigate in advance if your company has any restrictions using this platform. Investor contact: Martine Rambøl Hagen +47 91708918 martine.rambol.hagen@hydro.com

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS17.4.2024 08:00:00 CEST | Press release

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024 Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treat

Nilörn Interim Report Q1, 202417.4.2024 08:00:00 CEST | Press release

Period January - March Order intake increased by 5 percent to MSEK 233 (223)Revenue increased by 10 percent to MSEK 242 (221)Revenue adjusted for currency effects amounted to MSEK 243 (221), i.e., an underlying organic increase of 10 percentOperating profit amounted to MSEK 22.5 (16.9)Net profit for the period amounted to MSEK 16.7 (11.1)Earnings per share amounted to SEK 1.46 (0.97)Net cash excluding IFRS 16 amounted to MSEK 8 (43) Significant during the quarter The board has decided to propose to the annual general meeting a dividend of SEK 1.00 (5.00) per share, equivalent to MSEK 11.4 (57.0)Nilorngruppen has initiated a strategic collaboration with Worldfavor, strengthening the Nilorn:CONNECT solution and offer to our customers on their journey towards the Digital Product Passport. A presentation will be held today 17/4 at 08.30 am CET, where the CEO presents the report. You can participate by register on the link below: Registration Form For further information about Nilörn, pleas

Nilörn Delårsrapport Q1, 202417.4.2024 08:00:00 CEST | Pressemelding

Perioden januari - mars Orderingången ökade med 5 procent till 233 (223) MSEKOmsättningen i SEK ökade med 10 procent till 242 (221) MSEKOmsättningen justerat för valutaeffekter uppgick till 243 (221) MSEK, dvs en underliggande organisk ökning om 10 procentRörelseresultatet uppgick till 22,5 (16,9) MSEKPeriodens resultat uppgick till 16,7 (11,1) MSEKResultatet per aktie uppgick till 1,46 (0,97) SEKNettokassan (exklusive IFRS16) uppgick till 8 (43) MSEK Väsentliga händelser under kvartalet Styrelsen har beslutat att föreslå årsstämman en utdelning om 1,00 (5,00) kronor per aktie, motsvarande 11,4 (57,0) MSEKNilörn har inlett ett strategiskt samarbete med Worldfavor, vilket stärker lösningen Nilörn:CONNECT och erbjudandet till våra kunder på deras resa mot det Digitala Produktpasset En presentation kommer hållas idag 17/4 kl. 08.30, där VD presenterar rapporten. Du kan delta genom att registrera dig på nedanstående länk: Registration Form För ytterligare information om Nilörn, kontakta: K

HiddenA line styled icon from Orion Icon Library.Eye